NEW YORK – Medical device company Magnolia Medical announced Thursday a collaboration with Cardinal Health to distribute Magnolia's Steripath Gen2 Initial Specimen Diversion Device, which works to reduce blood culture contamination.
Cardinal Health will offer the device to hospitals as a standalone product or as part of a customizable best practice kit, with the goal of reducing false-positive diagnostic results for sepsis from blood contamination.
The Steripath Gen2 ISDD isolates a small volume of the initial blood culture, about 1.5 to 2 milliliters, which is the part of the blood culture most likely to contain contaminants. It has demonstrated up to a 92 percent reduction in blood culture contamination, according to Magnolia.
Financial and other terms of the deal were not disclosed.